Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes
Mutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs. We previously showed the transcriptome of a p53-d...
Saved in:
Published in | PloS one Vol. 7; no. 8; p. e42494 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
07.08.2012
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Mutations in the TP53 gene are very common in human cancers, and are associated with poor clinical outcome. Transgenic mouse models lacking the Trp53 gene or that express mutant Trp53 transgenes produce tumours with malignant features in many organs. We previously showed the transcriptome of a p53-deficient mouse skin carcinoma model to be similar to those of human cancers with TP53 mutations and associated with poor clinical outcomes. This report shows that much of the 682-gene signature of this murine skin carcinoma transcriptome is also present in breast and lung cancer mouse models in which p53 is inhibited. Further, we report validated gene-expression-based tests for predicting the clinical outcome of human breast and lung adenocarcinoma. It was found that human patients with cancer could be stratified based on the similarity of their transcriptome with the mouse skin carcinoma 682-gene signature. The results also provide new targets for the treatment of p53-defective tumours. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have read the journal’s policy and have the following conflicts: R.G.-E., J.-M.P., A.B.M.-C., M.S., P.L. and C.B. hold two patents for the genomic tests described in this study. Patent 1: Inventors: R. García Escudero, A.B. Martínez Cruz, M. Santos Lafuente and J.M. Paramio, Title: Genomic fingerprint of breast cancer, Request N°: PCT/ES2009/07028, Priority country: Spain, Priority date: 01/july/2009, Organism: CIEMAT. 2. Inventors: R. García Escudero, J.M. Paramio, Pedro Larrañaga, and Concepción Bielza, Title: Predictor test of global survival in lung adenocarcinoma, Request N°: P201031626, Priority country: Spain, Priority date: 05/november/2010, Organism: CIEMAT and UPM. In relation with employment, consultancy, or products in development the authors declare no conflict of interest. The conflict of interest that the authors are declaring does not alter their adherence to all the PLoS ONE policies on sharing data and materials. Conceived and designed the experiments: RGE MD JMP. Performed the experiments: RGE MD JFA JD GPS. Analyzed the data: RGE CB PL. Contributed reagents/materials/analysis tools: MS ABMC CL MT EMC JLRP MM RR JD GPS. Wrote the paper: RGE JMP. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0042494 |